TrialClinical and translational science2025

EDP-323, a First-In-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults.

Kimberly Elmore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.